Please try another search
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Matthew L. Posard | 56 | 2016 | Independent Chairman of the Board |
Herman Rosenman | 76 | 2019 | Independent Director |
Cynthia L. Collins | 65 | 2019 | Independent Director |
Kirk D. Malloy | 56 | 2022 | Independent Director |
Nathalie Gerschtein Keraudy | 44 | 2021 | Independent Director |
Mark Christopher Capone | 61 | 2022 | Independent Director |
Bret Christensen | 53 | 2023 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review